Payer Marketing in the 2027 Brand Plan

The 2027 brand plans coming together this month are landing in a payer environment that has shifted more in the last twenty-four months than in the decade before it. The IRA’s second round of Medicare price negotiations takes effect in January 2027, covering fifteen additional drugs. Electronic prior authorization requirements under CMS-0057 come online in the same window. And PBM reform activity is compressing rebate economics across multiple states and federal proposals at once. 2028 brings Part B drugs into negotiation for the first time, which means 2027 launches in certain categories are the last that will launch under the current rules.

For a brand team finalizing the 2027 plan right now, that context changes how payer strategy fits into the plan. Not as a downstream workstream owned by market access alone. As a set of decisions that shape the brand and the launch trajectory of the product from day one.

This piece is about where payer strategy fits in the 2027 brand plan, and what the strongest brand teams are building into their plans this September so that the payer thinking is present in every decision downstream of it.

Payer strategy has moved to the front of the brand plan

In the plans of five years ago, payer strategy typically arrived after the brand strategy had been set. The brand team built with HCPs and patients, and market access translated the brand into payer terms. That sequence worked when payer economics were stable enough for the translation to happen after the fact.

The economics are no longer stable enough for that sequence to work. IRA Round Two changes the net-price math for negotiated drugs and creates comparative pressure on adjacent therapies. PBM reform activity means copay assistance, formulary positioning, and network dynamics are all moving at the same time. Any-willing-pharmacy legislation and rebate pass-through requirements alter channel economics that brand plans have historically taken as fixed.

The brand teams building the strongest 2027 plans are treating payer strategy as an input to brand strategy, not an output of it. The value story gets developed in parallel with the brand story. Evidence plans are designed to answer payer questions from the beginning, not to fill payer objections retrospectively. And launch sequencing is built with payer moments as milestones, not as gates.

What the payer workstream looks like when it lives inside the plan

The value story is a shared document across brand, medical, and market access

The single most useful artifact in a payer-integrated 2027 plan is a value story that all three functions have contributed to and all three functions defend in the same language. Brand teams that produce a value story late, or produce it inside a market-access silo, end up spending launch cycles reconciling three different narratives when a payer, an HCP, and a patient are all being spoken to by the same brand.

The teams building the strongest plans are the ones producing a shared value story in Q1 or Q2 of the pre-launch year, and using it as the foundation every other workstream builds on. When done well, the same core narrative shows up in the payer dossier, in the HCP sales aid, and in the patient education material, each translated for the audience but grounded in the same evidence and the same claim.

Evidence generation is planned for payer answerability from the start

Payer expectations for evidence have shifted meaningfully in the past few years. Real-world evidence, budget impact models, indirect comparisons, and long-term outcomes data are now expected earlier in the launch cycle than they used to be. Brand plans that treat these as post-launch commitments end up scrambling to generate evidence after payer conversations have already begun.

The brand teams building the strongest 2027 plans are designing their evidence generation to answer payer questions from the beginning. That means naming, in the plan, which real-world data collection needs to be underway now, which indirect comparisons need to be modeled before payer engagement, and which health economics assets need to be defensible on the day of the first P&T conversation. The resulting evidence roadmap is a payer-informed document, not a scientific-affairs document produced in isolation.

The launch calendar has payer milestones as anchor points

In many pre-2020 launch plans, payer milestones were tracked separately from the brand launch calendar. Formulary submissions, P&T review windows, and payer engagement moments lived on a market-access spreadsheet that ran parallel to the brand’s Gantt chart.

The brand teams building strong 2027 plans are integrating these calendars. P&T review windows are visible to the whole brand team. Formulary decisions trigger a planned field response rather than an ad hoc one. And when a payer objection surfaces early in engagement, the brand adjusts its material set in real time rather than in the next quarterly review. Integration produces speed, and speed is what allows the brand to stay coherent across audiences even as payer signals move.

Field enablement is planned as one thing across HCP, patient, and payer

The field team that presents to an HCP is often the same team, or an adjacent one, that engages the payer account or supports the patient program. Brand plans that produce three different sets of materials for these audiences without a shared through-line put the field team in the position of translating between three narratives on the fly.

The teams building 2027 plans that support their field organizations are producing enablement assets designed to work as one system. The HCP sales aid, the payer-facing visual aid, and the patient support communications share visual identity, share language where it can be shared, and share a strategic core that the field team can hold in one head. That coherence is what lets the field stay fast and confident in every conversation they have.

Where the September window matters most

The plans being finalized this month are the plans that will resource the payer workstream for the next eighteen months. What is in the plan when it locks is what will be built. What is not in gets added later, and additions later cost more time and coordination than inclusions now.

For a brand team looking at the September budget review, the specific questions worth asking are the ones that are easiest to defer and hardest to add back in. Does the value story have enough time to be developed collaboratively across functions? Is the evidence plan reflecting what payers are asking for now, rather than what they were asking for in 2020? Does the launch calendar treat payer milestones as first-class events? And are the field team’s materials being built as one integrated system?

The brand teams whose 2027 launches will hold up in the market are the ones asking these questions this September, while the answers can still shape the plan.

If your team is finalizing the 2027 plan and wants to talk through how payer strategy is integrated into the brand plan, or how a payer marketing agency might support the workstreams where an outside partner strengthens the plan, that is a conversation we would welcome.